Second Sight Medical Products (NASDAQ:EYES) Shares Up 6.8%

Second Sight Medical Products Inc (NASDAQ:EYES) shares shot up 6.8% during mid-day trading on Friday . The company traded as high as $0.90 and last traded at $0.89, 75,754 shares traded hands during trading. A decline of 41% from the average session volume of 128,130 shares. The stock had previously closed at $0.83.

Separately, Zacks Investment Research upgraded shares of Second Sight Medical Products from a “hold” rating to a “buy” rating and set a $1.00 target price on the stock in a research report on Monday, August 12th.

The company has a debt-to-equity ratio of 0.12, a current ratio of 3.58 and a quick ratio of 3.39. The firm has a market capitalization of $106.42 million, a PE ratio of -1.71 and a beta of 2.27. The business’s 50-day moving average price is $0.81 and its 200-day moving average price is $0.83.

Second Sight Medical Products (NASDAQ:EYES) last announced its earnings results on Tuesday, August 6th. The medical device company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). The business had revenue of $1.28 million for the quarter, compared to analysts’ expectations of $0.45 million. Second Sight Medical Products had a negative return on equity of 248.94% and a negative net margin of 553.01%. Equities analysts forecast that Second Sight Medical Products Inc will post -0.29 earnings per share for the current year.

Second Sight Medical Products Company Profile (NASDAQ:EYES)

Second Sight Medical Products, Inc develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury.

Further Reading: Sell-Side Analysts

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with's FREE daily email newsletter.